CV Sciences Inc (QB) (CVSI) Quote

https://420intel.com/articles/2024/04/26/vegans-rejoice-farmers-switch-chickens-hemp

https://www.pinterest.com/email/click/?user

https://www.sciencedirect.com/science/article/abs/pii/S0278584624000824

https://www.nature.com/articles/s41432-024-01007-5

https://www.frontiersin.org/articles/10.3389/fvets.2024.1352314

https://www.pluscbdoil.com/cbd-products/pet-cbd-oil/pluscbd-pet-500mg.html

https://www.pluscbdoil.com/cbd-products/pet-cbd-for-dogs-calming-chews.html

https://www.pluscbdoil.com/cbd-products/pet-cbd-for-dogs-hip-and-joint.html

https://420intel.com/articles/2024/04/25/could-cbd-thc-help-quell-migraines

https://www.sciencedirect.com/science/article/pii/S2225411024000506

https://420intel.com/articles/2024/04/24/cannabis-market-booming-japan

CV Sciences +PlusCBD ?

https://hemptoday.net/japans-cbd-market-hits-154-million-and-should-keep-growing-report-suggests/

https://ir.cvsciences.com/press-releases/detail/207/cv-sciences-receives-formal-notice-of-patent-issuance-from

https://www.neurology.org/doi/10.1212/WNL.0000000000204925

https://www.neurology.org/doi/10.1212/WNL.0000000000206370

https://www.sciencedirect.com/science/article/abs/pii/S0889159124003556

Here is my take away-----
This financial stability and increased profitability are reflected in the company's P/E ratio, which stands at an attractive 2.05, suggesting that the stock may be undervalued relative to its earnings.

CV SCIENCES MAINTAINS MARKET LEAD AMID MARKET CHALLENGES.
https://ca.investing.com/news/stock-market-news/earnings-call-cv-sciences-maintains-market-lead-amid-industry-challenges-93CH-3328355
https://finance.yahoo.com/news/cv-sciences-inc-pnk-cvsi-210057560.html

AND:
https://www.procopio.com/cv-sciences-cultured-foods/

https://www.sdbj.com/food/cv-sciences-acquires-polands-cultured-foods/

https://www.prnewswire.com/news-releases/cv-sciences-inc-acquires-cultured-foods-to-enter-plant-based-food-market-opening-door-for-european-distribution-302012400.html

BS Post By Pinocchio Vs The Facts

💲💲💲💲💲💲💲💲💲💲💲💲

CVSI

Profitability
Profit Margin 19.38%

Operating Margin (ttm) -16.79%
Management Effectiveness

Return on Assets (ttm) 20.58%

Return on Equity (ttm) 291.82%

Income Statement
Revenue (ttm) 16M
Revenue Per Share (ttm) 0.10

Quarterly Revenue Growth (yoy) -1.80%

Gross Profit (ttm) N/A
EBITDA 3.85M

Net Income Avi to Common (ttm) 3.1M

Diluted EPS (ttm) 0.0200
Quarterly Earnings Growth (yoy) N/A

Balance Sheet
Total Cash (mrq) 1.32M

Total Cash Per Share (mrq) 0.01

Total Debt (mrq) 442k

Total Debt/Equity (mrq) 15.23%

Current Ratio (mrq) 1.30

Book Value Per Share (mrq) 0.02

Cash Flow Statement
Operating Cash Flow (ttm) 2.25M

Levered Free Cash Flow (ttm) 439.38k

⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️
💩💩💩💩💩💩💩💩💩💩💩💩

CWBHF

Profitability
Profit Margin -37.68%


Operating Margin (ttm) -61.84%

Management Effectiveness
Return on Assets (ttm) -14.72%

Return on Equity (ttm) -35.77%

Income Statement
Revenue (ttm) 63.16M

Revenue Per Share (ttm) 0.41

Quarterly Revenue Growth (yoy) -16.00%

Gross Profit (ttm) N/A
EBITDA -24.9M

Net Income Avi to Common (ttm) -23.8M
Diluted EPS (ttm) -0.1600

Quarterly Earnings Growth (yoy) N/A
Balance Sheet
Total Cash (mrq) 48.99m

Total Cash Per Share (mrq) 0.31

Total Debt (mrq) 60.44M

Total Debt/Equity (mrq) 108.78%

Current Ratio (mrq) 3.31
Book Value Per Share (mrq) 0.36
Cash Flow Statement

Operating Cash Flow (ttm) -15.39M
Levered Free Cash Flow (ttm) -3.89M

Yes, but it's the same out look they been giving for a while now.
"The Company's financial operating results and accumulated deficit, besides other factors, raise substantial doubt about the Company's ability to continue as a going concern. The Company will continue to pursue the actions outlined above, as well as work towards increasing revenue and operating cash flows to meet its future liquidity requirements. However, there can be no assurance that the Company will be successful in any capital-raising efforts that it may undertake, and the failure of the Company to raise additional capital could adversely affect its future operations and viability

https://www.mdpi.com/1999-4923/16/4/514

https://www.neurology.org/doi/10.1212/WNL.0000000000206411

https://mjbizdaily.com/hemp-industry-sees-rising-yields-prices-national-hemp-report/

https://www.tandfonline.com/doi/full/10.1080/15287394.2024.2338914

✅+PlusCBD RESERVE SLEEP
https://geekspin.co/4-20-gifts/

https://www.marijuanamoment.net/hemp-market-saw-growth-in-2023-after-major-declines-in-2022-usda-report-shows/

https://www.marijuanamoment.net/cbd-is-a-powerful-and-promising-treatment-for-crack-use-disorder-with-fewer-side-effects-than-conventional-therapies-study-finds/

https://www.sciencedirect.com/science/article/pii/S1043661824001208

https://www.cannabissciencetech.com/view/cbd-vs-thc-the-great-anxiety-debate

https://eiha-conference.org/

https://eiha.org/

Welcome Back Wise Wolf.

Get Ready for the Big Bang Theory YQU Understand. Have Mercy Have M&A Have Faith WQLF Ahooooooo

Wolfman Jack Said;

https://e-ajbc.org/journal/view.php?number=1496

Nosedive?????

https://420intel.com/articles/2024/04/12/head-us-fda-says-no-reason-dea-should-delay-cannabis-rescheduling

https://www.marijuanamoment.net/medical-marijuana-patient-enrollment-grew-610-since-2016-showing-increasing-cultural-acceptance-of-cannabis-federal-study-finds/

https://www.marijuanamoment.net/watch-live-fda-commissioner-testifies-on-hemp-regulatory-issues-at-congressional-hearing/

https://ir.cvsciences.com/sec-filings-email/content/0000950170-24-043834/cvsi_proxy_def_14a_2024.htm

https://www.neurology.org/doi/10.1212/CPJ.0000000000200285

https://www.sciencedirect.com/science/article/abs/pii/S0025619624000259

https://link.springer.com/article/10.1007/s10123-024-00505-x

https://www.liebertpub.com/doi/abs/10.1089/neu.2023.0539

AND ANOTHER NEW STUDY!
https://www.mdpi.com/1422-0067/25/7/3805

HELD LAST THURSDAY: FEDERAL CANNABIS REGULATION: CURRENT FDA AND STAKEHOLDER PERSPECTIVES.
https://www.fdli.org/2024/04/federal-cannabis-regulation-current-fda-and-stakeholder-perspectives/
Overview: CREATING CBD PRODUCT PATHWAYS AND OTHER POTENTIAL STEPS TO MOVE FEDERAL REGULATION FORWARD.

DRAFT GUIDANCE FOR INDUSTRY: NEW DIETARY INGREDIENT NOTIFICATION MASTER FILES FOR DIETARY SUPPLEMENTS.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-new-dietary-ingredient-notification-master-files-dietary-supplements
FDA ISSUES DRAFT GUIDANCE ON NDIN MASTER FILE FOR DIETARY SUPPLEMENTS.
https://www.wholefoodsmagazine.com/articles/16814-fda-issues-draft-guidance-on-ndin-master-files-for-dietary-supplements
CHPA also released a statement: CHPA is pleased to see FDA move forward on its commitment to release a separate draft guidance document this year on master files, “SAID SVP OF DIETARY SUPPLEMENTS DUFFY MACKAY....

OVERSIGHT COMMITTEE HEARING WITH FDA COMMISSIONER THURSDAY!
https://oversight.house.gov/release/oversight-committee-to-hold-hearing-with-fda-commissioner%EF%BF%BC/
Previous for follow-up:
https://oversight.house.gov/release/hearing-wrap-up-fdas-failure-to-regulate-cbd-threatens-consumer-access-to-safe-products/

HOUSE COMMITTEE HEARING WITH FDA HEAD TO TALK HEMP REGULATIONS...THURSDAY!
Provide a Regulatory pathway for CBD as dietary supplements and FOOD and BEVERAGE ADDITIVES.
https://www.marijuanamoment.net/house-committee-schedules-hearing-with-fda-head-to-talk-hemp-regulations-and-other-issues-next-week/

https://cannabiswire.com/2024/04/05/fda-officials-discuss-future-of-cannabis-regulation-at-food-drug-law-institute/

Partnership ?
https://imbucanna.com/

https://hemptoday.net/medical-cbd-maker-will-pay-out-7-5-million-to-settle-suit-over-valuation-executive-bonuses/

https://europepmc.org/article/ppr/ppr829199

Hilarious Glads Thong, You May want to read this:
https://www.investing.com/news/stock-market-news/earnings-call-cv-sciences-maintains-market-lead-amid-industry-challenges-93CH-3359226
P.S. A extreme risk is with struggling competitor: CHARLOTTES WEB: You May want to read the lengthy Risks Summary with CHARLOTTES WEB.
https://www.investing.com/news/stock-market-news/earnings-call-cv-sciences-maintains-market-lead-amid-industry-challenges-93CH-3359226

CVSI Annual Report: questions Company's viability

From CV Sciences' 2023 Annual Report dated March 29, 2024:

https://pubmed.ncbi.nlm.nih.gov/38384931/